

BACIL PHARMA LIMITED

CIN: L24200MH1987PLC043427

Registered Office: G2 & G3, Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai - 400099;
Tel: 22618452/22661541; Tel/Fax: 22618327; Email Id: bacilpha@yahoo.com/bacilpharma07@gmail.com; Website: www.bacilpharma.com

Date: 26th June, 2026

To,
The General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400001

Scrip Code: 524516

Subject: Outcome of the Meeting of the Board of Directors held on 26th June, 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of Bacil Pharma Limited, at its meeting held today i.e. 26th June, 2026 has, inter alia, considered and approved the following:

- The Board, after due deliberations, considered and approved the proposal to raise funds by the Company up to Rs. 50 crores, through one or more permissible modes, including but not limited to a Rights Issue, Preferential Issue, issue of convertible securities, warrants or any other securities or instruments, or any other permissible mode or combination thereof, subject to the receipt of such statutory, regulatory and other approvals as may be required under applicable laws.
- The Board further authorized the Managing Director, Chief Financial Officer, Company Secretary and such other officials of the Company, either jointly or severally, to evaluate the various fund-raising options, appoint intermediaries, undertake necessary due diligence, negotiate the terms and conditions, finalize the structure of the proposed fund raising and undertake all such acts, deeds and things as may be necessary or expedient in connection therewith.

The Board noted that the mode of fund raising, size of the issue, pricing, class of securities, terms and conditions and other related matters shall be determined at the appropriate stage, based on the recommendations of the management and advisors, prevailing market conditions and subject to applicable statutory and regulatory approvals, including the approval of the shareholders of the Company, wherever required.

The Company shall make the requisite disclosures to the Stock Exchange in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as and when any definitive decision is taken by the Board in respect of the proposed fund raising.

The meeting of the Board commenced at 4 P.M. and concluded at 6 P.M.

Kindly take the above information on record.

Thanking You,

Yours faithfully,

For Bacil Pharma Limited

Mrs. Chaitali Kalpataru Shah
Director & CFO
DIN: 11167778